Skip to main content

Advertisement

SpringerLink
Log in

Significant Relation of Tissue Inhibitor of Matrix Metalloproteinase-2 and Its Combination With Matrix Metalloproteinase-2 to Survival of Patients With Cancer of Uterine Cervix

  • Articles
  • Published:
Reproductive Sciences Aims and scope Submit manuscript

Abstract

Tissue inhibitor of matrix metalloproteinase-2 (TIMP-2) has high affinity for matrix metalloproteinase-2 (MMP-2). Few studies simultaneously investigate their implication in prognosis of patients with cervical cancer. We used reverse transcription-polymerase chain reaction and immunohistochemical method for cervical tissues and microarrays to investigate the association among TIMP-2, MMP-2, clinicopathological parameters, and prognosis of patients with cancer. Our results showed that cancer tissues exhibited less TIMP-2 expression and patients with pelvic lymph node metastasis had less TIMP-2 expression. Positive TIMP-2 constellated with negative MMP-2 indicated lower recurrence probability and better overall survival. The protective effect of TIMP-2 expression may overcome the adverse effect of MMP-2 expression in terms of disease-free interval and overall survival while neither TIMP-2 nor MMP-2 alone can be used to predict outcome. We suggest that following patients other than those with positive TIMP-2 and negative MMP-2 expression more closely and intensely may improve their prognosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Docherty AJP, Murphy G. The tissue metalloproteinase family and the inhibitor TIMP: a study using cDNAs and recombinant proteins. Annll Rheum Dis. 1990;49:469–479.

    Google Scholar 

  2. Stetler-Stevenson WG, Brown PD, Onisto M, Levy AT, Liotta LA. Tissue inhibitor of metalloproteinases-2 (TIMP-2) mRNA expression in tumor cell lines and human tumor tissues. J Biol Chem. 1990;265(23):13933–13938.

    CAS  PubMed  Google Scholar 

  3. Goetzl EJ, Banda MJ, Leppert D. Matrix metalloproteinases in immunity. J Immunol. 1996;156(1):1–4.

    CAS  PubMed  Google Scholar 

  4. Garzetti GG, Ciavattini A, Lucarini G, Goteri G, De Nictolis M, Biagini G. Microinvasive cervical carcinoma and cervical intraepithelial neoplasia: biologic significance and clinical implications of 72-kDa metalloproteinase immunostaining. Gynecol Oncol. 1996;61(2):197–203.

    Article  CAS  PubMed  Google Scholar 

  5. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2002;2(3):161–174.

    Article  CAS  PubMed  Google Scholar 

  6. Chambers AF, Matrisian LM. Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst. 1997;89(17):1260–1270.

    Article  CAS  PubMed  Google Scholar 

  7. Liotta LA, Kohn EC. The microenvironment of the tumour-host interface. Nature. 2001;411(6835):375–379.

    Article  CAS  PubMed  Google Scholar 

  8. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res. 2003;92(8):827–839.

    Article  CAS  PubMed  Google Scholar 

  9. Tokuraku M, Sato H, Murakami S, Okada Y, Watanabe Y, Seiki M. Activation of the precursor of gelatinase A/72 kDa type IV collagenase/MMP-2 in lung carcinomas correlates with the expression of membrane-type matrix metalloproteinase (MT1-MMP) and with lymph node metastasis. Int J Cancer. 1995;64(5):355–359.

    Article  CAS  PubMed  Google Scholar 

  10. Sternlicht MD, Bissell MJ, Werb Z. The matrix metalloproteinase stromelysin-1 acts as a natural mammary tumor promoter. Onco-gene. 2000;19(8):1102–1113.

    Article  CAS  Google Scholar 

  11. Lohi J, Wilson CL, Roby JD, Parks WC. Epilysin: a novel human matrix metalloproteinase (MMP-28) expressed in testis and keratinocytes and in response to injury. J Biol Chem. 2001;276(13): 10134–10144.

    Article  CAS  PubMed  Google Scholar 

  12. Toi M, Ishigaki S, Tominaga T. Metalloproteinases and tissue inhibitors of metalloproteinases. Breast Cancer Res Treat. 1998; 52(1–3):113–124.

    Article  CAS  PubMed  Google Scholar 

  13. Edwards DR. The tissue inhibitors of metalloproteinases (TIMPs). In: Clendeninn, NJ, Appelt, K Matrix Metalloproteinase Inhibitors in Cancer Therapy. Totowa, NJ: Humana; 2001:67–84.

  14. Brew K, Dinakarpandian D, Nagase H. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta. 1477. 2000;465:469–483.

    Google Scholar 

  15. Baker AH, Ahonen M, Kähäri V-M. Potential applications of tissue inhibitor of metalloproteinase (TIMP) overexpression for cancer gene therapy. Adv Exp Med Biol. 2000;465:469–483.

    Article  CAS  PubMed  Google Scholar 

  16. Gomez DE, Alonso DF, Yoshiji H, Thorgeirsson UP. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol. 1997;74(2):111–122.

    CAS  PubMed  Google Scholar 

  17. Murphy AN, Unsworth EJ, Stetler-Stevenson WG. Tissue inhibitor of metalloproteinases-2 inhibits bFGF-induced human microvascular endothelial cell proliferation. J Cell Physiol. 1993;157(2):351–358.

    Article  CAS  PubMed  Google Scholar 

  18. Li H, Lindenmeyer F, Grenet C, et al. AdTIMP-2 inhibits tumor growth, angiogenesis, and metastases, and prolongs survival in mice. Hum Gene Ther. 2001;12(5):515–526.

    Article  CAS  PubMed  Google Scholar 

  19. Wang PH, Ko JL, Tsai HT, et al. Clinical significance of matrix metalloproteinase-2 in cancer of uterine cervix: a semiquantitative study of immunoreactivities using tissue array. Gynecol Oncol. 2008;108(3):533–542.

    Article  CAS  PubMed  Google Scholar 

  20. Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med. 2006;355(10):983–991.

    Article  CAS  PubMed  Google Scholar 

  21. Al-Haddad S, Zhang Z, Leygue E, et al. Psoriasin (S100A7) expression and invasive breast cancer. Am J Pathol. 1999; 155(6):2057–2066.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Handra-Luca A, Bilal H, Bertrand JC, Fouret P. Extra-cellular signalregulated ERK-1/ERK-2 pathway activation in human salivary gland mucoepidermoid carcinoma: association to aggressive tumor behavior and tumor cell proliferation. Am J Pathol. 2003; 163(3):957–967.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Chang H, Su JM, Huang CC, et al. Using a combination of cytochrome P450 1B1 and beta-catenin for early diagnosis and prevention of colorectal cancer. Cancer Detect Prev. 2005;29(6):562–569.

    Article  CAS  PubMed  Google Scholar 

  24. Figueira RC, Gomes LR, Neto JS, Silva FC, Silva ID, Sogayar MC. Correlation between MMPs and their inhibitors in breast cancer tumor tissue specimens and in cell lines with different metastatic potential. BMC Cancer. 2009;9:20–30.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Remacle AG, Noël A, Duggan C, et al. Assay of matrix metalloproteinases types 1, 2, 3 and 9 in breast cancer. Br J Cancer. 1998;77(6):926–931.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Campo E, Tavassoli FA, Charonis AS, Stetler-Stevenson WG, Liotta LA, Merino MJ. Evaluation of basement membrane components and the 72 kDa type IV collagenase in serous tumours of the ovary. Am J Pathol. 1992;6(5):500–507.

    Article  Google Scholar 

  27. Duffy MJ, Maguire TM, Hill A, McDermott E, O’Higgins N. Metalloproteinases: role in breast carcinogenesis, invasion and metastases. Breast Cancer Res. 2000;2(4):252–257.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Voloshenyuk TG, Gardner JD. Estrogen improves TIMP-MMP balance and collagen distribution in volume-overloaded hearts of ovariectomized females. Am J Physiol Regul Integr Comp Physiol. 2010;299(2):R683–R693.

    Article  CAS  PubMed  Google Scholar 

  29. Lewandowski KC, Komorowski J, Mikhalidis DP, et al. Effects of hormone replacement therapy type and route of administration on plasma matrix metalloproteinases and their tissue inhibitors in postmenopausal women. J Clin Endocrinol Metab. 2006;91(8):3123–3130.

    Article  CAS  PubMed  Google Scholar 

  30. Ring P, Johansson K, Höyhtyä M, Rubin K, Lindmark G. Expression of tissue inhibitor of metalloproteinases TIMP-2 in human colorectal cancer-a predictor of tumour stage. Br J Cancer. 1997;76(6):805–811.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Curran S, Dundas SR, Buxton J, Leeman MF, Ramsay R, Murray GI. Matrix metalloproteinase/tissue inhibitors of matrix metalloproteinase phenotype identifies poor prognosis colorectal cancers. Clin Cancer Res. 2004;10(24):8229–8234.

    Article  CAS  PubMed  Google Scholar 

  32. Peng L, Xing X, Li W, et al. PRL-3 promotes the motility, invasion, and metastasis of LoVo colon cancer cells through PRL-3-integrin β1-ERK1/2 and-MMP2 signaling. Mol Cancer. 2009;8:110–122.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Sakata K, Shigemasa K, Nagai N, Ohama K. Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary. Int J Oncol. 2000;17(4):673–681.

    CAS  PubMed  Google Scholar 

  34. Sheu BC, Lien HC, Ho HN, et al. Increased expression and activation of gelatinolytic matrix metalloproteinases is associated with the progression and recurrence of human cervical cancer. Cancer Res. 2003;63(19):6537–6542.

    CAS  PubMed  Google Scholar 

  35. Trudel D, Fradet Y, Meyer F, Harel F, Têtu B. Membrane-type-1 matrix metalloproteinase, matrix metalloproteinase 2, and tissue inhibitor of matrix proteinase 2 in prostate cancer: identification of patients with poor prognosis by immunohistochemistry. Hum Pathol. 2008;39(5):731–739.

    Article  CAS  PubMed  Google Scholar 

  36. Rigg AS, Lemoine NR. Adenoviral delivery of TIMP1 or TIMP2 can modify the behavior of pancreatic cancer and can have a significant antitumor effect in vivo. Cancer Gene Therapy. 2001;8(11):869–878.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan

    Po-Hui Wang MD, PhD, Jiunn-Liang Ko PhD, Shun-Fa Yang PhD, Yi-Torng Tee MD, PhD, Chih-Ping Han MD, PhD,  Long-Yau Lin MD, PhD &  Shiuan-Chih Chen MD, PhD

  2. School of Medicine, Chung Shan Medical University, Taichung, Taiwan

    Po-Hui Wang MD, PhD, Yi-Torng Tee MD, PhD, Chih-Ping Han MD, PhD,  Long-Yau Lin MD, PhD &  Shiuan-Chih Chen MD, PhD

  3. Department of Obstetrics and Gynecology, Chung Shan Medical University Hospital, Taichung, Taiwan

    Po-Hui Wang MD, PhD, Yi-Torng Tee MD, PhD, Chih-Ping Han MD, PhD,  Long-Yau Lin MD, PhD &  Yang-Tse Shih MD

  4. Institute of Medical and Molecular Toxicology, Chung Shan Medical University, Taichung, Taiwan

    Jiunn-Liang Ko PhD

  5. Department of Clinical Laboratory, Chung Shan Medical University Hospital, Taichung, Taiwan

    Shun-Fa Yang PhD

  6. Department of Medical Research, Chung Shan Medical University Hospital, Taichung, Taiwan

    Shun-Fa Yang PhD

  7. School of Nursing, Chung Shan Medical University, Taichung, Taiwan

    Hsiu-Ting Tsai PhD

  8. Department of Nursing, Chung Shan Medical University Hospital, Taichung, Taiwan

    Hsiu-Ting Tsai PhD

  9. Clinical Trial Center, Chung Shan Medical University Hospital, Taichung, Taiwan

    Chih-Ping Han MD, PhD

  10. Department of Family and Community Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan

    Shiuan-Chih Chen MD, PhD

Authors
  1. Po-Hui Wang MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jiunn-Liang Ko PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shun-Fa Yang PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hsiu-Ting Tsai PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yi-Torng Tee MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Chih-Ping Han MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Long-Yau Lin MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Shiuan-Chih Chen MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Yang-Tse Shih MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Po-Hui Wang MD, PhD, Long-Yau Lin MD, PhD, Shiuan-Chih Chen MD, PhD or Yang-Tse Shih MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wang, PH., Ko, JL., Yang, SF. et al. Significant Relation of Tissue Inhibitor of Matrix Metalloproteinase-2 and Its Combination With Matrix Metalloproteinase-2 to Survival of Patients With Cancer of Uterine Cervix. Reprod. Sci. 18, 798–808 (2011). https://doi.org/10.1177/1933719111398143

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1177/1933719111398143

Keywords

Search

Navigation